Top Story Today
A Fifth Weapon for a Cancer That Keeps Evolving
The FDA approved Jideytro (zidesamtinib), a targeted pill for ROS1-positive lung cancer patients whose tumors have already outsmarted prior drugs. In 117 previously treated patients, 44% saw meaningful tumor shrinkage, and 78% of responders were still going strong at one year. The brain data might be the headline: a 48% intracranial response rate in previously treated patients. GSK, which acquired developer Nuvalent, plans to seek a first-line label expansion later this year after the drug posted an 89% response rate in untreated patients.
Why it matters: ROS1-positive NSCLC hits only 1-2% of lung cancer patients, but in a decade they've gone from zero targeted options to five. Jideytro fills a critical gap for patients who've run out of alternatives, and a first-line expansion could reshape treatment sequencing entirely.
Read more →Policy and Regulation
Congress Just Told the FDA to Stop Defaulting to Lab Rats
The House passed the FDA Modernization Act 3.0 without a single objection, forcing the agency to replace every reference to "animal" tests with "nonclinical" tests in its regulations within one year. Preclinical and discovery costs run roughly $430 million per approved drug, and nonclinical alternatives can run 1.5 to 30 times cheaper. The bill heads to the Senate, where companion legislation is already waiting.
Read more →The Senate Declared War on Pharma's Patent Fortresses
The Senate unanimously passed the Affordable Prescriptions for Patients Act in 2023, capping the patents a biologic maker can assert against biosimilar challengers at 20. That matters because blockbusters like Humira carry 132 patents (90% filed after launch), delaying competition by up to a decade. The CBO estimates $3 billion in taxpayer savings over ten years. The bill now heads to the House.
Read more →Clinical and Commercial
Roche Killed Its Lupus T-Cell Engager, Then Doubled Down
Roche terminated its lupus T-cell engager RG6382 after early data fell short, concluding that cancer-grade immune weapons may be too blunt for autoimmune disease. But the company isn't retreating: its anti-CD20 antibody Gazyva posted strong lupus phase 3 results (76.7% vs. 53.5% on placebo), and it's advancing autoimmune cell therapies through a $1.5 billion Poseida acquisition.
Read more →Zepbound's New Back Door to Cheaper Prices
Lilly is selling the highest Zepbound doses in single-dose vials for $449 per month, roughly 60% cheaper than the $1,086 autoinjector pens. Same molecule, same dose, different packaging. With 88% of commercially insured patients facing restricted GLP-1 coverage and CVS Caremark dropping Zepbound entirely, the vial option creates a lifeline for cash-paying patients willing to use a syringe.
Read more →Pfizer's Prostate Cancer Combo Gets the FDA's Fast Lane
The FDA granted Priority Review to Pfizer's TALZENNA plus XTANDI combination for earlier-stage metastatic prostate cancer, with a decision expected in Q4 2026. The Phase 3 trial showed a 52% reduction in progression or death risk. The castration-sensitive space is a significant market, as the majority of newly diagnosed metastatic prostate cancer patients are initially castration-sensitive.
Read more →Science and Discovery
The $5 Billion Bet That AI Can Crack Chronic Disease
The NIH joined the Trump administration's Genesis Mission, a $5 billion, 15-agency AI initiative aiming to double the productivity and impact of American science and engineering within a decade. The biomedical arm, the Bio Genesis sub-initiative, has a goal to cut in half the time it takes for scientific discoveries to reach patients, with $1.2 billion in aligned funding and plans for AI-driven autonomous labs. Critics worry about political control over research priorities, but the computing infrastructure alone could reshape how drugs are discovered.
Read more →AI-Built Proteins That Sit Quietly Until They Smell Trouble
An international team published AI-designed proteins in Nature Biotechnology that act like programmable molecular switches, lying dormant until they detect a specific target, then snapping to life. Some achieved 200-fold dynamic ranges, and graphene-wired versions detected hormones at sub-nanomolar concentrations. The real breakthrough is the modular framework: pick a target, design a binder, plug it in.
Read more →Cancer's Favorite Weapon Just Switched Sides
Oblenio Bio raised $62 million (led by Pfizer Ventures) to develop a trispecific T-cell engager designed from scratch for autoimmune disease, not cancer. In monkeys, their molecule achieved complete B-cell and plasma cell depletion with no cytokine release syndrome. The immune systems rebuilt with fresh, non-memory cells; the biological signature of a true immune reset.
Read more →